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was inadequate response from traditional disease-modifying anti-rheumatic drugs 
(DMARDs) alone (54.9%), followed by symptom control (13.4%). Among the remaining 
responses, clinical data (e.g., results from clinical trials) was cited most frequently in 
the UK (17.1%) compared to Germany/Spain (9.0%/4.7%), while personal experience 
was cited most in Germany (15.3%) vs. UK/Spain (2.7%/0.9%). Inadequate response 
to DMARDs was most frequently reported for adalimumab (61.5%) vs. etanercept 
(46.9%) or other biologics (40.2%); inadequate DMARD symptom control was more 
cited for etanercept (18.8%) vs. adalimumab (11.1%) or other biologics (9.8%). Among 
the 23 patients who switched to a second biologic agent, 72.7% were switched due 
to inadequate response to the first biologic agent. ConClusions: Across the 
three study countries, prescribers most frequently initiated biologic therapy due 
to inadequate response or lack of symptom control on traditional DMARDs. Other 
reasons varied by country, however differences across biologic agents prescribed 
were minimal.
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objeCtives: Cervical Dystonia (CD), the most common adult-onset dystonia, is 
characterised by involuntary contractions of the cervical muscles that result in 
abnormal, sustained, and painful postures of the head, neck and shoulders. Annual 
prevalence rate of CD in Europe is approximately 117 per million. To date, very 
few studies assessed the burden of the disease, and those published focused on 
costs of specific treatments. The objective of this study was to describe health care 
resource utilisation of patients with CD during the first year after diagnosis in 
the UK. Methods: In this retrospective cohort study, adult patients with a first 
ever diagnosis of primary or secondary CD (Read code: F138200 Spasmodic torti-
collis) between January 2007 and December 2011 were selected from The Health 
Improvement Network (THIN), a large UK Primary Care database. Patients were 
required to have a follow-up time of at least 24 months after diagnosis. Analyses 
performed described demographic and clinical characteristics at diagnosis and 
all-cause utilization of CD-related health care resources including treatment dur-
ing follow up. Results: This study included 4,497 patients, 65.40% were female, 
median age at diagnosis was 41 years old and 8.05% were diagnosed with depression. 
During that first year, patients had on average 6 visits to the GP (SD: 5.45) and were 
newly referred most frequently to the orthopaedist (5.09%); less than 2% of patients 
had an all-cause hospitalisation and less than 1% underwent neurosurgery; 80.23% 
were managed with pharmacological treatment for CD, and the most commonly 
prescribed drugs were analgesics (69.85%) and benzodiazepines (41.23%); 14.65% 
received physical therapy. ConClusions: This study provides first-time estimates 
of the health care resource utilisation related to management of patients with CD 
in UK during the first year. To describe the complete burden of CD further research 
will have to investigate secondary care data and longer time horizon.
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objeCtives: To analyze the potential cost savings associated with utilization of 
a quota for biosimilar RA medicines in a biologic naïve but potentially biologic 
eligible population (those defined as severe). Methods: High patient numbers 
in rheumatoid arthritis (RA) and biologic therapy costs place significant pressures 
on health care budgets. Currently biologic therapies are underutilized in severe RA 
(DAS Score ≥ 3.7) patient populations that may be eligible for treatment. Biosimilar 
treatments are expected to reach the market (for the top 3 molecules adalimumab, 
etanercept and infliximab) by 2017 and may provide an avenue to reduce treatment 
costs and increase patient access to these agents. Biologic naïve RA populations 
were estimated for France, Germany and the UK as severe RA patients are assumed 
to be eligible for biologic therapy. Total cost of applying biologic treatment to a 
50% quota of the estimated eligible patient population was compared to a situa-
tion of initiating patients on a biosimilar equivalent with a price point 30% lower 
than the originator. Reinvestment potential was calculated, defining how many 
more patients could be treated with yearly savings. Results: By 2017, when all 3 
biosimilars are expected to be available, the assumed 50% quota resulted in yearly 
savings of € 98 million for the UK, € 351 million for Germany and € 26 million for 
France compared to the budget impact of using the originator. If these savings were 
reinvested potentially 40%, 36% and 39% of the remaining biologic naïve patients 
could be initiated on biosimilar treatment in the UK, Germany and France respec-
tively. ConClusions: The cost savings from biosimilar adoption in naive severe 
RA patients presented potentially increase access by removing budgetary pressures 
from health care systems. Proactive payer encouragement for biosimilar utilization 
is necessary through the use of guidelines and prescription quotas so that health 
care systems can realize significant savings.
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At 18 months, drug survival rate of the mix of first-line biologics was 71.8% [95% 
CI: 60.1% - 80.6%]. ConClusions: Claims database is a useful tool to describe the 
medical management of RA patients. These observations suggest that BA clinical 
use in RA disease management in France is similar to other existing European 
registries data.
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objeCtives: Etanercept 50mg/week (ETN50) has demonstrated efficacy in rheu-
matoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) 
patients. In certain patients in sustained clinical remission, a dose reduction to 
etanercept 25 mg/week (ETN25) could be done. Determine the economic impact 
of ETN25 in RA, PA and AS patients in sustained clinical remission. Methods: 
Observational, retrospective cohort of patients treated with ETN50 that achieve 
and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during 1 year and slow 
worsening of structural changes, enrolled in an off-label program (January 2006-June 
2013) to switch ETN50 to ETN25. Economical impact was assessed using Enbrel® 
Spanish official prices. Results: From January 2006 to June 1, 2013, 98 RA, 40 PA, 
47 AS patients were treated with ETN50; 39 (24%) patients (18 women; age 53±7 
years; 24 RA, 7 PA, 8 AS) received ETN25 for at least 0.5 years (2.6±2.0 years; range 
0.5-7.3 years). At June 1, 2013, 29 (74%) patients continued on ETN25. RA patients: 17 
continued on ETN25, 5 patients discontinued due to reactivation of RA (4 switched to 
ETN50 and 1 switched to adalimumab, all regained clinical remission) and 2 patients 
due to adverse reactions. PA patients: 4 continued on ETN25, 2 patients discontinued 
due to reactivation of PA (switched to ETN50 regaining clinical remission) and 1 
patient due to adverse reaction. All AS patients continued on ETN25. Total associ-
ated savings with ETN 25 throughout the 7-year observation period were 622.073€ , 
leading to treat 52 additional patients with ETN50 for a year without increasing ETN 
total costs. ConClusions: ETN25 produces cost savings when used in patients 
in clinical remission for at least 1 year with ETN50. At a time when therapy cost is 
an unavoidable component of health care treatment decisions, ETN25 could be a 
cost-effective option for selected RA, PA and AS patients.
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objeCtives: Switching or dose escalation of TNF inhibitors is an option for rheu-
matoid arthritis (RA) patients unresponsive or with a partial response to first-line 
treatment. Drug costs increase with higher dosing but the frequency and impact 
of dose escalation on other costs is not well known. A literature review of biologic 
dose escalation in RA was conducted to assess how often it occurs and the economic 
impact to payers. Methods: A search of PubMed, EMBASE, Cochrane, and Centre of 
Disseminated Reviews was conducted for TNF inhibitors in inflammatory arthritis 
diseases. Searches were focused on dose escalation and economic terms in RA. 
Limits were Human, English and time frame (2003 to 2013). A weighted proportion 
of dose escalators in RA was calculated for each drug as an alternative to reporting 
ranges. Results: Forty-one publications were identified with 36 reporting values 
for dose escalation in RA. The proportion of dose escalators varied widely: adali-
mumab 7.5 to 36%, etanercept 0 to 22%, and infliximab 0 to 80%. Various definitions 
of dose escalation led to the wide range. The weighted proportion of dose escalators 
for each drug was adalimumab 14.9%, etanercept 4.9%, and infliximab 41.7%. Six 
studies reported economic data comparing dose escalators to non-dose escalators. 
Adalimumab drug costs increased 27 to 43% with total costs increasing 28 to 34%; 
infliximab drugs costs increased 6 to 75%, RA-related costs increased 25 to 54%, 
and total costs increased 15% to 35%. Lowest costs were reported with etanercept: 
drug costs increased 3.2 to 19%, RA-related costs increased 4.5%, and total costs 
increased 2.2 to 15%. ConClusions: Pooled results demonstrated dose escalation 
in RA occurred most frequently with infliximab and least frequently with etaner-
cept. Not only were biologic costs increased, but also RA-related and total costs. 
Etanercept was associated with the lowest cost increases.
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objeCtives: This study aimed to describe the rationale for selection of initial bio-
logic therapy and changes in biologic therapy among patients with RA in Germany, 
Spain, and the United Kingdom (UK). Methods: This retrospective, observational 
medical chart review captured patient data via 118 Spanish, German, and British 
rheumatologists. Patients( ≥ 18 years) had a confirmed diagnosis of RA between 
January 2008 and December 2010, and received a biologic therapy for ≥ 3 months and 
had ≥ 12 months of follow-up. Physicians recorded all RA regimens and rationale for 
drug selection. Results: The 656 patients (n= 328; Germany: n= 111, Spain: n= 106, 
UK: n= 111) were 71.3% female, had a mean (standard deviation) age of 48.3 (12.6) 
years at diagnosis and mean 28-joint Disease Activity Score of 5.1±1.2 at biologic 
initiation. Patients most frequently initiated biologic therapy with adalimumab 
(41%) or etanercept (38%). The most common reason for initial biologic treatment 
